Skip to main content
    G

    Grace Therapeutics, Inc. (GRCE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.75
    -0.06 (-3.31%)

    Market Cap: $38.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Grace Therapeutics, Inc. (GRCE) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Grace Therapeutics reported EPS of -$0.11. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    63%(19/30)
    Avg Surprise
    -34.16%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.21
    Range-$0.21 - -$0.21
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.21-1.5%
    60d ago-$0.21-1.5%
    30d ago-$0.18-13.0%
    7d ago-$0.18-13.0%
    Current-$0.21
    Revenue Consensus
    N/A
    RangeN/A
    1 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.12
    RangeN/A
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Next Report

    GRCE's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    Earnings History

    Of the 30 quarters below that had an estimate, GRCE beat 19 and missed 11. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 500.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.11-$0.21-$0.21 - -$0.21N/AN/AN/A10 up, 1 downNov 12, 2026
    Jun 30, 2026-$0.91-$0.18-$0.18 - -$0.18-405.56%MissN/A11 up, 0 downAug 13, 2026
    Mar 31, 2026-$0.08-$0.20N/A+60.00%Beat-260.0%11 up, 0 downJun 18, 2026
    Dec 31, 2025-$0.19-$0.39-$0.39 - -$0.39+51.28%BeatN/A10 up, 1 downFeb 12, 2026
    Sep 30, 2025-$0.08-$0.34-$0.34 - -$0.34+76.47%BeatN/A11 up, 0 downNov 13, 2025
    Jun 30, 2025-$0.29-$0.31N/A+6.45%BeatN/A11 up, 0 downAug 12, 2025
    Mar 31, 2025$0.05-$0.40-$0.40 - -$0.28+112.55%BeatN/A31 up, 0 downJun 23, 2025
    Dec 31, 2024-$0.51-$0.46N/A-11.67%MissN/AN/AN/AFeb 13, 2025
    Sep 30, 2024-$0.42-$0.50N/A+16.79%BeatN/AN/AN/ANov 13, 2024
    Jun 30, 2024-$0.33-$0.36N/A+8.33%BeatN/AN/AN/AAug 9, 2024
    Mar 31, 2024-$0.36-$0.47N/A+24.13%BeatN/AN/AN/AJun 21, 2024
    Dec 31, 2023-$0.28-$0.31N/A+9.68%BeatN/AN/AN/AFeb 12, 2024
    Sep 30, 2023-$0.31-$0.35N/A+11.43%BeatN/AN/AN/ANov 13, 2023
    Jun 30, 2023-$0.48-$0.37N/A-29.73%MissN/AN/AN/AAug 11, 2023
    Mar 31, 2023-$0.65-$0.14N/A-364.29%MissN/AN/AN/AJun 23, 2023
    Dec 31, 2022-$0.72-$1.01N/A+28.71%BeatN/AN/AN/AFeb 14, 2023
    Sep 30, 2022-$0.11N/AN/AN/AN/AN/AN/AN/ANov 14, 2022
    Jun 30, 2022-$0.10N/AN/AN/AN/AN/AN/AN/AAug 11, 2022
    Mar 31, 2022-$0.31-$1.00N/A+69.00%BeatN/AN/AN/AJun 21, 2022
    Dec 31, 2021-$0.69-$0.62N/A-11.29%MissN/AN/AN/AFeb 14, 2022
    Sep 30, 2021-$0.03N/AN/AN/AN/AN/AN/AN/ANov 10, 2021
    Jun 30, 2021-$0.08N/AN/AN/AN/AN/AN/AN/AAug 12, 2021
    Mar 31, 2021-$0.24-$0.04N/A-500.00%Miss-209.1%N/AN/AJun 22, 2021
    Dec 31, 2020-$1.83-$2.50N/A+26.80%BeatN/AN/AN/AFeb 9, 2021
    Sep 30, 2020-$3.77-$3.17N/A-18.93%MissN/AN/AN/ANov 16, 2020
    Jun 30, 2020-$3.17-$3.89N/A+18.51%BeatN/AN/AN/AAug 13, 2020
    Mar 31, 2020$0.22-$0.09N/A+344.44%BeatN/AN/AN/AJun 29, 2020
    Dec 31, 2019-$8.64-$4.59N/A-88.24%MissN/AN/AN/AFeb 14, 2020
    Sep 30, 2019-$16.32-$5.28N/A-209.09%MissN/AN/AN/ANov 13, 2019
    Jun 30, 2019-$7.20-$8.09N/A+11.00%BeatN/AN/AN/AAug 14, 2019
    Mar 31, 2019-$0.02-$0.11N/A+79.27%BeatN/AN/AN/AJun 26, 2019
    Dec 31, 2018-$3.36-$4.80N/A+30.00%BeatN/AN/AN/AFeb 14, 2019
    Sep 30, 2018-$29.76-$6.72N/A-342.86%MissN/AN/AN/ANov 14, 2018
    Jun 30, 2018-$11.04-$12.96N/A+14.81%BeatN/AN/AN/AAug 14, 2018
    Mar 31, 2018-$12.14N/AN/AN/AN/AN/AN/AN/AJun 29, 2018
    Dec 31, 2017-$19.20-$13.44N/A-42.86%MissN/AN/AN/AMar 31, 2018
    Sep 30, 2017-$11.71N/AN/AN/AN/AN/AN/AN/ANov 14, 2017
    Jun 30, 2017-$6.74N/AN/AN/AN/AN/AN/AN/AAug 15, 2017
    Dec 31, 2016-$8.10N/AN/AN/AN/AN/AN/AN/AJan 13, 2017
    Sep 30, 2016-$8.05N/AN/AN/AN/AN/AN/AN/ANov 30, 2016
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was -$0.64, after -$1.21 the year before. It was -$21.58 for the year ended Mar 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026-$0.64N/A
    Mar 31, 2025-$1.21N/A
    Mar 31, 2024-$1.43N/A
    Mar 31, 2023-$1.58N/A
    Mar 31, 2022-$1.11N/A
    Mar 31, 2021-$9.01N/A
    Mar 31, 2020-$31.94N/A
    Mar 31, 2019-$44.18N/A
    Mar 31, 2018-$76.82N/A
    Mar 31, 2016-$21.58N/A

    Frequently Asked Questions About GRCE

    What EPS do analysts expect from GRCE next quarter?

    The consensus EPS estimate for Grace Therapeutics for the quarter ending Dec 31, 2026 is -$0.21 from 1 analyst, with estimates from -$0.21 to -$0.21.

    How often does GRCE beat earnings estimates?

    Grace Therapeutics beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of -11.71%.